Hemophilia

Latest News

Pfizer’s Hympavzi Cuts Bleeding by 93% in Hemophilia A and B Patients with Inhibitors, Phase 3 Trial Finds
Pfizer’s Hympavzi Cuts Bleeding by 93% in Hemophilia A and B Patients with Inhibitors, Phase 3 Trial Finds

July 8th 2025

Out of the more than 800,000 people worldwide living with hemophilia, around 20% of those with hemophilia A and 3% with hemophilia B develop inhibitors, preventing their bodies from responding to standard clotting factor therapies.

Switching from Emicizumab to Mim8 Without a Washout Period Is Safe and Well-Tolerated in Hemophilia A Patients
Switching from Emicizumab to Mim8 Without a Washout Period Is Safe and Well-Tolerated in Hemophilia A Patients

July 1st 2025

Gene Therapy Cuts Bleeding and Medicine for Hemophilia B Patients for Over a Decade
Gene Therapy Cuts Bleeding and Medicine for Hemophilia B Patients for Over a Decade

June 17th 2025

Half of Severe Hemophilia A Cases Have No Family History, Delaying Diagnosis but Not Raising Inhibitor Risk
Half of Severe Hemophilia A Cases Have No Family History, Delaying Diagnosis but Not Raising Inhibitor Risk

June 12th 2025

Video Interviews
Podcasts

More News

© 2025 MJH Life Sciences

All rights reserved.